Opinion|Videos|August 19, 2024
Future Directions of BTK Inhibitors in Leukemia and Lymphoma
Experts discuss future directions of BTK inhibitors.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let’s discuss anticipated (or just presented) data from ASCO 2024 on the treatment of CLL. What data or insights are you most looking forward to coming out of ASCO 2024?
- How might emerging biomarkers influence the development and use of BTK inhibitors in CLL?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer
2
FDA Panel Backs 6 Peptides for Compounding
3
Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD
4
Boston Panel Confronts Access and Coordination Gaps in Obesity Care
5